Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2018 ASCO Annual Meeting but not presented at the Meeting, can be found online only.
Efficacy of primary prophylactic GCSF in patients receiving docetaxel based chemotherapy for breast cancer.
2018 ASCO Annual Meeting
J Clin Oncol 36, 2018 (suppl; abstr e12516)
Author(s): Jamal M Zekri, Azhar Nawaz, Haleem J. Rasool, Imran Ahmad, Hossam Abdel Rahman, Ahmed Allithy, Ehab Mosaad Abdelghany, Kamel Farag, Refaei Belal Ibrahim, Mohamed Youssef Deibas, Mohamed Kamal Kamel, Reyad Dada; Professor, Al-Faisal University, Consultant Oncologist, King Faisal Special Hospital & Research Centre, Jeddah, Saudi Arabia; King Faisal Specialist Hospital & Research Center-Jeddah Branch, Jeddah, Saudi Arabia; Mayo Clinic Health System, La Crosse, WI; King Faisal Specialist Hosp and Research Ctr, Al-Faisal University, Jeddah PO Box 40047, AR, Saudi Arabia; KFSHRCJ, Jeddah, Saudi Arabia; Assistant Consultant King Faisal Specialist Hospital & Research Center-Jeddah Branch, Jeddah, Saudi Arabia; King Faisal Specialist Hospital and Research Center, Cancer National Institute/Cairo University, Jeddah, Saudi Arabia; Assistant Professor of Medical Oncology, Faculty of Medicine Mansoura University, Egypt. Assistant Consultant Oncologist, King Faisal Special Hospital and Research Centre (Jeddah), Jeddah, Saudi Arabia; Clinical Oncology Department Al-Hussein University Hospital, Faculty of Medicine Al-Azhar University, Cairo, Egypt; Cairo University, MRCP Ireland, Cairo, Egypt; King Faisal Specialist Hospital and Research Center, Medical College, Al-Faisal University, Saudi Arabia, Jeddah, Saudi Arabia
Background: Primary prophylactic Granulocyte Colony Stimulating Factor (PP-GCSF) is recommended for patients receiving single agent docetaxel (SAD) and docetaxel combination regimens (DCR) to reduce risk of febrile neutropenia (FN). This study aims to investigate the benefit of PP-GCSF in these patients in real life daily setting. Methods: All consecutive patients (n = 276) with breast cancer who received SAD or DCR between years 2015 and 2017 were included. Starting dose of Docetaxel was 80 mg/m2 in SAD and was variable in different DCRs. Data was collected retrospectively. Chi-square and Mann–Whitney–Wilcoxon tests were used as appropriate to detect significance of differences. The outcome presented in this abstract is limited to findings related to 1st and 2nd cycles of chemotherapy. Results of comprehensive analyses will be presented at the conference. Results: Median age was 50 (21-75) years. Treatment intent was curative in 233 (84.4%) and palliative in 43 (15.6%) patients. 193 (69.9%) received PP-GCSF after first cycle of chemotherapy while 83 (30.1%) did not. FN was less frequent in patients who received SAD (P = 0.046) and in those who received primary PP-GCSF (P = 0.02) compared to DCR and no GCSF prophylaxis respectively (Table). There was a tendency to shorter admission days after FN (P = 0.098) and less cycle 2 chemotherapy dose reduction (P = 0.525) and delays (P = 0.256) in patients who received PP-GCSF compared to those who did not. Conclusions: PP-GCSF significantly reduces the risk of FN in patients receiving docetaxel based chemotherapy. It may also shorten duration of admission after 1st cycle of docetaxel based therapy and enables more optimal subsequent treatment delivery.
|Number||Rate of FN after 1st cycle||Mean duration (range) of admission for FN in days||Cycle 2 dose reduction||Cycle 2 dose delay|
|All patients||276||25 (9.1%)||4.56 (1-15)||60/265 (22.6%)||39/265 (14.7%)|
|SAD||138/276 (50%)||8/138 (5.8%)||4 (1-6)||29/131 (22.1%)||19/131 (14.5%)|
|DCR||138/276 (50%)||17/138 (12.3%)||4.82 (1-15)||31/134 (23.1%)||20/134 (14.9%)|
|Received PP-GCSF||193 (69.9%)||12/193 (6.2%)||3.67 (1-7)||40/185 (21.6%)||24/184 (13%)|
|No PP-GCSF||83 (30.1%)||13/83 (15.7%)||5.38 (1-15)||20/80 (25%)||15/79 (19%)|
1. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.